Telesis Bio (NASDAQ:TBIO – Get Free Report) will likely be releasing its resultson Thursday, August 6th. Analysts expect the company to post earnings of ($6.39) per share and revenue of $2.5330 million for the quarter.
Telesis Bio Price Performance
Shares of TBIO stock opened at $0.00 on Tuesday. The company has a fifty day moving average price of $0.01 and a two-hundred day moving average price of $0.04. Telesis Bio has a one year low of $0.00 and a one year high of $0.15. The stock has a market cap of $1,982.20, a P/E ratio of -0.00 and a beta of 2.43.
About Telesis Bio
Telesis Bio, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel immunotherapies that harness the body’s innate immune system. The company’s proprietary platform designs small-molecule and biologic agonists of pattern recognition receptors (PRRs), including toll-like receptors (TLRs) and NOD-like receptors, to stimulate targeted immune responses. Telesis Bio’s lead programs are advancing through preclinical and early clinical development in immuno-oncology and vaccine adjuvant applications.
The company’s pipeline includes synthetic pathogen-associated molecular patterns (PAMPs) that are engineered to act as immune stimulants.
Featured Stories
- Five stocks we like better than Telesis Bio
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Telesis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telesis Bio and related companies with MarketBeat.com's FREE daily email newsletter.
